Thrombocytopenia Market to Exhibit CAGR of 4.69% for the Study Period of 2018-2030, Backed by ...

Retrieved on: 2021-02-11 15:56:15

Tags for this article:

Click the tags to see associated articles and topics

Thrombocytopenia Market to Exhibit CAGR of 4.69% for the Study Period of 2018-2030, Backed by .... View article details on hiswai:

Excerpt

Rozanolixizumab (UCB7665): UCB Biopharma; Rilzabrutinib (PRN-1008): Principia Biopharma; TAK-755 (BAX930/SHP655): Baxalta/Takeda ...

Article found on: www.prnewswire.com